Novo-founded Orbis Solutions Cracks Macrocycle Synthesis Challenges, Secures $26 Million Funding

1. Orbis, a company founded by Novo, has made significant progress in overcoming the complexities associated with the chemistry of macrocycle synthesis.
2. Macrocycles, large cyclic molecules, present unique challenges in their production, particularly regarding incomplete reactions and the difficulty of achieving efficient macrocyclization steps.
3. Despite existing methods like diversity-oriented synthesis, one-bead-one-compound techniques, and various biological display methods, there remains a need for more extensive and target-focused macrocycle libraries.
4. Orbis' achievement in cracking the chemistry code for macrocycles is expected to contribute to advancements in drug discovery and other applications where macrocycles play an essential role.
5. To support its efforts, Orbis has raised $26 million in funding, indicating investor confidence in the potential impact of its solutions on the field of macrocycle research and development.

These details cannot be found directly in the search results provided, but they are inferred based on the information about the difficulties faced in creating macrocycle libraries and the importance of developing better methods for their synthesis and screening.